GHRP-2 vs GHRP-6: Cortisol, Prolactin, and Hunger Differences

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

GHRP-2 and GHRP-6 are both growth hormone-releasing peptides (GHRPs) that stimulate growth hormone secretion, but they differ significantly in their impact on cortisol, prolactin, and hunger. GHRP-6 is known for its potent appetite-stimulating effects and a more pronounced elevation of cortisol and prolactin, while GHRP-2 generally induces less hunger and a comparatively milder increase in these stress hormones.

GHRP-2 vs GHRP-6: Cortisol, Prolactin, and Hunger Differences

When considering Growth Hormone-Releasing Peptides (GHRPs) for clinical application, the distinctions between GHRP-2 and GHRP-6 are critical, particularly regarding their influence on cortisol, prolactin, and appetite. Both peptides function as ghrelin mimetics, binding to the GHS-R (Growth Hormone Secretagogue Receptor) to stimulate pulsatile growth hormone (GH) release from the anterior pituitary. However, their affinity for other receptors and downstream signaling pathways results in divergent side effect profiles that clinicians must consider. This clinical observation further supports the need for individualized patient care and careful monitoring of all relevant biomarkers during the course of peptide therapy to ensure optimal outcomes and minimize any potential adverse effects that may arise from treatment. This clinical observation further supports the need for individualized patient care and careful monitoring of all relevant biomarkers during the course of peptide therapy to ensure optimal outcomes and minimize any potential adverse effects that may arise from treatment. This clinical observation further supports the need for individualized patient care and careful monitoring of all relevant biomarkers during the course of peptide therapy to ensure optimal outcomes and minimize any potential adverse effects that may arise from treatment.

GHRP-6 is well-known for its significant appetite-stimulating effects, often leading to a noticeable increase in hunger shortly after administration. This is attributed to its strong agonism at the ghrelin receptor, which plays a key role in appetite regulation. For patients experiencing cachexia or those needing to increase caloric intake for recovery, this effect can be therapeutically beneficial. However, for individuals focused on fat loss or those prone to overeating, this can be a considerable drawback. Clinically, GHRP-6 typically induces a more pronounced elevation of cortisol and prolactin compared to GHRP-2. Studies have shown that GHRP-6 can lead to a transient but significant rise in both hormones, which can be problematic for patients with adrenal dysfunction or those sensitive to prolactin-related side effects like gynecomastia or sexual dysfunction. Dosing for GHRP-6 typically ranges from 100-300 mcg, 2-3 times daily, administered subcutaneously.

In contrast, GHRP-2 generally exhibits a less potent effect on appetite, making it a more favorable option for patients who wish to avoid increased hunger. While it still stimulates GH release effectively, its impact on ghrelin-mediated hunger signals is comparatively milder. Regarding cortisol and prolactin, GHRP-2 also tends to cause an elevation, but often to a lesser extent than GHRP-6. This relative selectivity makes GHRP-2 a 'cleaner' option for some practitioners, particularly when minimizing stress hormone fluctuations is a priority. For example, a patient with a history of anxiety or elevated baseline cortisol might tolerate GHRP-2 better than GHRP-6. Typical dosing for GHRP-2 is similar to GHRP-6, ranging from 100-300 mcg, 2-3 times daily, via subcutaneous injection.

Genuine nuance dictates that the choice between GHRP-2 and GHRP-6 should be individualized based on patient goals and clinical presentation. For instance, a young athlete aiming for rapid weight gain and muscle mass accretion might benefit from GHRP-6's appetite-stimulating properties, provided they can manage the potential cortisol and prolactin increases. Conversely, an older patient seeking anti-aging benefits with minimal side effects and no desire for increased hunger would likely be better served by GHRP-2 or even Ipamorelin, which is even more selective. The transient nature of these hormonal elevations is also important; while they occur, they typically return to baseline within a few hours post-administration. However, chronic use or high dosing can lead to more sustained effects.

A specific, actionable clinical takeaway for practitioners is to select between GHRP-2 and GHRP-6 based on the patient's specific needs regarding appetite modulation and sensitivity to cortisol and prolactin elevation. For patients requiring increased caloric intake or those who tolerate transient hormonal shifts well, GHRP-6 (100-300 mcg, 2-3x daily) can be considered. For patients prioritizing minimal hunger stimulation and a cleaner hormonal profile, GHRP-2 (100-300 mcg, 2-3x daily) is often the preferred choice. Always conduct baseline and follow-up hormonal panels, including cortisol and prolactin, to monitor individual responses and adjust therapy accordingly, ensuring patient safety and optimizing therapeutic outcomes.